Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54

European Heart Journal

The benefit of ticagrelor for long-term secondary prevention in patients with prior MI and ≥1 additional risk factor appeared more marked in patients continuing on or re-starting after only a brief interruption of P2Y12 inhibitors, compared with patients off them for > 1 year.

 

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

The Lancet

The ABC-bleeding score, using age, history of bleeding, and three biomarkers (haemoglobin, cTn-hs, and GDF-15 or cystatin C/CKD-EPI) score performed better than HAS-BLED and ORBIT scores in patients with AF on anticoagulants from the ARISTOTLE and RE-LY trials.

 

Indiscriminate Testing for Heparin-Induced Thrombocytopenia: A Teachable Moment

JAMA Internal Medicine

This case report illustrates the ramifications of overtesting, and advises that it is crucial to consider other causes of thrombocytopenia and determine pretest probability to guide management whenever heparin-induced thrombocytopenia is suspected.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients

Heart

Compared with medically managed patients newly started on clopidogrel (CP) in TRILOGY ACS trial, patients previously on CP had a higher risk of CV events. There were no differences in outcomes as stratified by prior CP use by randomised treatment assignment (prasugrel or CP).

 

Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

Circulation

Review of 11 RCTs (n=33,051 who received predominantly newer-generation drug eluting stents) found moderately strong evidence that prolonged dual antiplatelet therapy entails a trade-off between reductions in stent thrombosis and MI and increases in major haemorrhage.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study

The Lancet Haematology

Analysis suggests extended treatment with edoxaban (ED) is as effective as warfarin (WF) [incidence recurrent venous thromboembolism between 3 and 12 months = 0·3% (11 of 3633) with ED and 0.4% (14 of 3594) with WF; HR 0.78, 95% CI 0.36–1.72] and linked to less major bleeding.

 

Astra Zeneza announces that ticagrelor fails to meet primary efficacy endpoint in SOCRATES trial

PharmaTimes

The drug failed on the primary efficacy endpoint of increasing the time to first occurrence of stroke (ischaemic or haemorrhagic), myocardial infarction or death vs aspirin in patients who have experienced an acute ischaemic stroke or transient ischaemic attack.

 

Positive results in first six months for anticoagulant hospital referral service

Pharmaceutical Services Negotiating Committee

Since launch (6 months) 138 patients have been referred to Swindon and Wiltshire Local Pharmaceutical Committee anticoagulant referral service with Great Western Hospital. This report highlights the positive outcomes experienced.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be
found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

 

Safer Prescribing — A Trial of Education, Informatics, and Financial Incentives

New England Journal of Medicine

Trial in 34 Scottish practices found a complex intervention combining professional education, informatics, and financial incentives reduced rate of high-risk prescribing of antiplatelets and NSAIDs (OR 0.63; 95% CI, 0.57 to 0.68; p<0.001) and may have improved clinical outcomes.

 

Reimagining anticoagulation clinics in the era of direct oral anticoagulants

Circulation: Cardiovascular Quality and Outcomes

Review outline 3 key purposes that a reimagined clinic would serve: assist patients/clinicians with selecting most appropriate drug/dose, help patients minimise risk of serious bleeding with careful long-term monitoring/peri-procedural management, and encourage ongoing adherence.

 

Non-vitamin K antagonist oral anticoagulants (NOACs) for the management of venous thromboembolism

Heart

This review aims to provide the reader with an understanding of the importance of venous thrombosis in cardiovascular medicine, the mode of action of different oral anticoagulants, and the uses, risks and benefits of each non-vitamin K antagonist oral anticoagulant.

 

Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

European Heart Journal

This review summarises the current evidence from randomised and observational studies on the cardiovascular safety of non-aspirin NSAIDs and presents a position for their use.

 

Risk of Cerebral Venous Thrombosis (CVT) in Obese Women

JAMA Neurology

This case-control study (185 cases, 6134 controls) found an increased risk of CVT among obese women (OR, 2.63, 95% CI, 1.53-4.54).The risk is 30-fold higher in obese women using oral contraceptives (OCs) compared with normal-weight women not using OCs.

 

The Use of Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Patients with History of Intra-Cranial Hemorrhage

Circulation

This review of people with atrial fibrillation and prior Intra-Cranial Haemorrhage (ICH), found that the NNT (warfarin vs anti-platelet) for preventing 1 ischaemic stroke was lower than NNH for 1 ICH if CHA2DS2-VASc≥6 (37vs56). NNT was higher than NNH if CHA2DS2-VASc<6 (63vs53).

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

Anticoagulation in coronary intervention

European Heart Journal

This review article summarises the current status of anticoagulation for percutaneous coronary intervention and the results of most recent trials and gives recommendations for different clinical scenarios.

 

Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes

Heart

This review article covers the mechanism of action and roles of antithrombotic therapy in non-ST-segment elevation acute coronary syndromes. Treatments covered are aspirin, clopidogrel, ticagrelor, vorapaxar, unfractionated heparin, low-molecular-weight heparins and fondaparinux.

 

Coagulation Factor IX (recombinant) albumin fusion protein (albutrepenonacog alfa), for haemophila B approved for use in US

US Food and Drug Administration

This has been approved in the US, for use in children and adults, following two trials of patients aged 1-61 years. It was shown to be effective in controlling bleeding episodes and managing perioperative bleeding.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty

Thrombosis and Haemostasis

This study (n=351) found no significant differences between rivaroxaban (RV) and enoxaparin (EN) in surgical wound complications, with similar rates of venous thromboembolic (VTE) events. Only wound oozing continued longer in RV/EN than in placebo group for patients <60 years.

 

Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation

European Heart Journal
Treatment with this device can reduce risk of stroke, major bleeding, and death vs. other therapeutic strategies, which may offset additional upfront costs of device. Benefits are most apparent in those with higher baseline thromboembolic risk or unsuitable for anticoagulation.

 

Is the HAS-BLED score useful in predicting post-extraction bleeding in patients taking warfarin? A retrospective cohort study

BMJ Open

Japanese study of 258 cases (462 teeth) who had undergone tooth extraction (TE) whilst on warfarin found HAS-BLED score alone could not predict post TE bleeding. Concomitant use of antiplatelets was a risk factor. No episodes of bleeding required more than local measures.

 

New product: Octaplex (blood coagulation factors IX, II, VII, and X) 1000IU

electronic Medicines Compendium

This is licensed for treatment of bleeding and perioperative prophylaxis of bleeding in acquired deficiency of prothrombin complex coagulation factors (CFs), and in congenital deficiency of vitamin K dependent CFs II and X when purified specific CF product is not available.

 

New product: Exembol (argatroban) Multidose 100 mg/ml concentrate for solution for infusion

electronic Medicines Compendium

Exembol is licensed as anticoagulation in adults with heparin-induced thrombocytopenia type II who need parenteral antithrombotic therapy. Diagnosis should be confirmed by heparin induced platelet activation assay or equivalent. However, such confirmation must not delay treatment.

 

NIHR Signal: Extending anticoagulant treatment beyond three months reduces the risk of recurrent blood clots

National Institute for Health Research Signal

This commentary discussing a systematic review of 7 studies (n=6778), which found that warfarin, NOACs and aspirin all significantly reduced the rate of recurrent clots in patients treated for >3 months, notes a non-significant trend towards major bleeding with active vs. placebo.

 

Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis

American Journal of Medicine

This meta-analysis of 5 RCTs (n=1418) suggests no effect of elastic compression stockings on postthrombotic syndrome. Effects however remain uncertain as results differed substantially, and there was significant heterogeneity between trials.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

European CHMP issues positive opinion on granting marketing authorisation for eftrenonacog alfa (Alprolix)

European Medicines Agency

Eftrenonacog alfa, an antihaemorrhagic, blood coagulation factor IX, is intended for the treatment and prophylaxis of bleeding in patients with haemophilia B. It will be available as 250 IU, 500 IU, 1000 IU, 2000 IU and 3000 IU powder and solvent for solution for injection.

 

European CHMP starts review on medicines containing dienogest 2mg and ethinylestradiol 0.03mg used for acne

European Medicines Agency

The review has been requested by MHRA because of concerns that benefits of these agents have not been sufficiently demonstrated in treatment of acne. MHRA was also concerned about venous thromboembolism risk, which has not been sufficiently characterised for this combination.

 

Non-vitamin K antagonist oral anticoagulants (NOACs) (KTT16)

National Institute for Health and Care Excellence

This document summarises the evidence-base on NOACs. It is a key therapeutic topic which has been identified to support medicines optimisation. It is not formal NICE guidance.

 

Stopping vs. Continuing Aspirin before Coronary Artery Surgery

New England Journal of Medicine

RCT (n=2100) found that administration of preoperative aspirin resulted in neither a lower risk of death or thrombotic complications (occurred in 202 [19.3%] on aspirin and 215 [20.4%] placebo) nor a higher risk of major haemorrhage leading to reoperation (1.8% vs. 2.1% placebo).

 

Improving anticoagulation in patients with atrial fibrillation using the GRASP AF audit tool

West Hampshire CCG and Boehringer Ingelheim Ltd

This audit tool (developed by Boehringer Ingelheim and PRIMIS) was used to improve stroke prevention in patients with AF. The project specifically focussed on patients receiving antiplatelet monotherapy and no treatment despite being at high risk of stroke, based on NICE CG180.

 

FibCLOT (human fibrinogen) obtains first Marketing Authorisations in Europe

Biospace Inc.

EU marketing authorisations for this product to treat patients with a congenital fibrinogen deficiency have been granted in Germany, Denmark and Hungary. Thirteen more marketing authorisations are expected in Europe in the coming months.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis

European Heart Journal

Guidelines recommend decisions on oral anticoagulation be made independently of classification into paroxysmal AF (PAF) or non-PAF. This study suggests NPAF may be linked to increased risk of stroke and mortality vs. PAF, thus AF type may need to be considered.

 

Boehringer announces that idarucizumab (Praxbind®) is now available to be used commercially in England, Ireland and Wales

Biospace Inc.

According to Boehringer, the Health Technology Appraisal bodies in these countries agreed that idarucizumab, which specifically reverses anticoagulant effect of dabigatran, is eligible for full reimbursment without the need for a full appraisal.

 

The past and future of haemophilia: diagnosis, treatments, and its complications

The Lancet

In this seminar, the authors provide an overview of the diagnosis of haemophilia and describe the clinical manifestations and treatment (both on-demand and prophylactic). Inhibitor formation as a complication of replacement therapy and its treatment is also discussed.

 

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions

British Journal of Clinical Pharmacology

This retrospective analysis (n=17,701) found that major bleeding events were more common with NSAID use (vs non-use) in both standard of care (SOC) and rivaroxaban groups. NSAID use had no influence on thromboembolic events in either SOC or rivaroxaban groups.

 

Biologics License Application for andexanet alfa to reverse anticoagulant activity of direct and indirect Factor Xa inhibitors accepted for review by FDA

Biospace Inc.

Andexanet alfa is being developing as an antidote for use in patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as in life-threatening or uncontrolled bleeding or for emergency surgery and urgent procedures.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54

European Heart Journal

This review on dual antiplatelet therapy (DAPT) discusses the implications of the PEGASUS-TIMI 54 study which showed that patients with a history of ACS and at high risk of further ischaemic events, may benefit from prolonged ticagrelor-based DAPT.

 

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism

Cochrane Database of Systematic Reviews

Moderate to high quality evidence suggests that there are no differences between these agents and standard anticoagulation for long-term treatment of PE for the outcomes recurrent PE, recurrent venous thromboembolism, DVT, all-cause mortality and major bleeding.

 

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

 

Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial

The Lancet Haematology

Additional catheter-directed thrombolysis resulted in a persistent and increased clinical benefit vs. control during follow-up for up to 5 years, supporting use of this intervention in patients with extensive proximal DVT. However, it did not lead to better quality of life.

 

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1

European Heart Journal

The following scenarios are covered: stable CAD/PVD; cardioversion, ablation and anti-arrhythmics; mechanical valves, patients with time in therapeutic range of >70% on warfarin; patients with single stroke risk factor; and patients with a single first episode of paroxysmal AF.

 

Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2

European Heart Journal

The following scenarios are covered: post CVA/TIA, acute stroke requiring thrombolysis/thrombectomy, initiating/restarting treatment after CVA/TIA, dialysis, the elderly, high risk of GI bleeding, hypertension, adherence and compliance.

 

Pfizer issues oral anticoagulants toolkit to support delivery of Medicines Use Reviews (MURs) and the New Medicine Service (NMS)

Pharmaceutical Services Negotiating Committee

The PSNC and Pharmacy Voice have endorsed this toolkit, hard copies of which are available to order from the Access Pfizer website (need to register on website and have an Alliance Healthcare account number or Pfizer customer account number).

 

Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies

Stroke

Review of 10 studies did not find link between use of NSAIDs and increased risk of haemorrhagic stroke (pooled RR 1.09; 95% CI, 0.98–1.22), although individually, this risk was modestly elevated in diclofenac and meloxicam users (1.27, 1.02–1.59 and 1.2, 1.08–1.50, respectively).

 

Summary of antidotes to NOACs (inlcuding those currently in development) which could impact NOAC use in the future

London Medicines Evaluation Network

This briefing aims to provide an update on idarucizumab (launched), andexanet alpha (potential launch 2017), and aripazine (phase 2 studies), including the evidence base underpinning their use as antidotes to NOACs.

 

Call for independent review of ROCKET-AF trial of rivaroxaban and Bayer’s response

British Medical Journal

There is a call for an independent investigation into the ROCKET-AF trial underpinning use of rivaroxaban to prevent ischaemic stroke in non-valvular AF after a BMJ investigation found defective point of care INR device was used in warfarin arm of trial.

 

Impact of pharmacy care upon adherence to cardiovascular medicines: a feasibility pilot controlled trial

European Journal of Hospital Pharmacy

This study of 71 patients randomised to receive community pharmacy interviews (face-to-face or phone consultation) for 6 months after discharge following acute treatment for a coronary event showed statistically significantly improved adherence in the intervention group.

 

Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial

Journal of Clinical Oncology

Data from this open-label RCT (n=2,202) show that these heparins do not improve overall survival or metastasis-free survival in lung cancer patients, although there was a statistically significant reduction in VTE (at the cost of increased clinically relevant non-major bleeding).

 

A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome (ACS)

European Heart Journal

An overview of current data examining sex differences in the use of, and outcomes related to, antithrombotic therapy for patients with ACS, concludes that antithrombotic therapies for acute MI are similar in efficacy in males & females, but females are at higher risk of bleeding.

 

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions

Cochrane Database of Systematic Reviews

Despite discovery of a beneficial effect of systemically administered tranexamic acid and epsilon aminocaproic acid in preventing postop bleeding, the limited number of RCTs do not provide definite evidence of efficacy of antifibrinolytic therapy in this setting.

 

Mobile Telephone Text Messaging for Medication Adherence in Chronic Disease A Meta-analysis

JAMA Internal Medicine

According to this meta-analysis, mobile phone text messaging approximately doubles the odds of medication adherence. This increase translates into adherence rates improving from 50% (assuming this baseline rate in patients with chronic disease) to 67.8% (absolute increase 17.8%).

 

Acute Limb Ischemia and Outcomes With Vorapaxar in Patients with Peripheral Artery Disease: Results From TRA2°P-TIMI 50

Circulation

This RCT (n=3,787) of patients with symptomatic peripheral artery disease found that vorapaxar reduced total acute limb ischaemia events (ALI) events (94 vs 56, HR=0.59, 95% CI= 0.38-0.93) and first ALI events (HR 0.58, 95% CI= 0.39-0.86).

 

European CHMP adopts positive opinion for factor X (Coagadex) for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency

European Medicines Agency

Factor X, an antihaemorrhagic, works as replacement therapy and temporarily increases plasma levels of factor X, helping to prevent and control bleeding. Factor X has orphan status and is being reviewed under accelerated assessment.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services

 

Page 7 of 18